Table 1.
Characteristics of EBV reactivations on all patients treated with immunosuppressive therapy
| HC | HCS | RC | CP | P* | |
|---|---|---|---|---|---|
| Courses, no. (%)† | 33 (33) | 25 (25) | 14 (14) | 26 (26) | |
| Courses in patients seropositive for EBV, no. (%) | 33 (100) | 24 (96) | 13 (93) | 24 (92) | NS |
| EBV reactivations in seropositive patients, no. (%) | 29 (88) | 22 (92) | 13 (100) | 19 (80) | NS |
| Peak EBV copies, median (range) | 4 380 (480-160 000) | 5 000 (260-466 000) | 270 000 (6 700-1 025 000) | 10 000 (620-655 000) | |
| Mean of log peak EBV copies (95% CI) | 3.8 (3.6-4.0) | 3.6 (3.2-4.0) | 5.2 (4.8-5.6) | 4.1 (3.7-4.6) | < .001 |
| Time to peak EBV | |||||
| Median, d (range) | 17 (4-55) | 21 (4-182) | 19 (7-27) | 6 (4-70) | |
| Mean, d (95% CI) | 18 (13-23) | 43 (21-66) | 17 (12-22) | 12 (5-20) | .003 |
| Positivity for EBV, wk | |||||
| Median (range) | 6 (1-25) | 5 (1-28) | 12 (4-24) | 2 (0-19) | |
| Mean (95% CI) | 8 (6-10) | 10 (6-14) | 13 (9-17) | 3 (1-5) | .001 |
HC indicates horse ATG/CsA; HCS, horse ATG/CsA/sirolimus; RC, rabbit ATG/CsA; CP, alemtuzumab; NS, not statistically significant.
*
P values are for the comparison among the 4 groups; P value is computed based on the ANOVA F test for the log-transformed peak EBV copies.
†
EBV serostatus was not determined in 1 patient in the HC arm (not tabulated) prior to immunosuppressive therapy.